Kliniske studier for Lymfom i Kansas
7 studier for Lymfom søker deltakere på steder i Kansas.
Byer i Kansas
Offisiell studietekst (engelsk)
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- University of Kansas Medical Center, Kansas City
RekruttererFase 1
Alder 18 til 100 · Alle kjønn · Oppdatert 15. sep. 2026 · NCT05798897Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Kansas City
RekruttererFase 3
Alder 18 til 18 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Kansas City VA Medical Center, Kansas City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06624085A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Kansas Cancer Center, Westwood
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- University of Kansas Cancer Center, Westwood
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
RekruttererFase 2
Alder 18 til 66 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06859424A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Kansas, Westwood
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. nov. 2025 · NCT05643742Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.